Alpine Immune Sciences (ALPN) Stock Forecast, Price Target & Predictions
ALPN Stock Forecast
Alpine Immune Sciences stock forecast is as follows: an average price target of $55.00 (represents a -15.35% downside from ALPN’s last price of $64.97) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.
ALPN Price Target
The average price target for Alpine Immune Sciences (ALPN) is $55.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $65.00 to $44.00. This represents a potential -15.35% downside from ALPN's last price of $64.97.
ALPN Analyst Ratings
According to 5 Wall Street analysts, Alpine Immune Sciences's rating consensus is 'Hold'. The analyst rating breakdown for ALPN stock is 0 'Strong Buy' (0.00%), 2 'Buy' (40.00%), 3 'Hold' (60.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Alpine Immune Sciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 11, 2024 | Robert Driscoll | Wedbush | $65.00 | $47.04 | 38.18% | 0.05% |
| Apr 11, 2024 | Michael Ulz | Morgan Stanley | $65.00 | $47.04 | 38.18% | 0.05% |
| Apr 09, 2024 | Vamil Divan | Guggenheim | $55.00 | $38.53 | 42.75% | -15.35% |
| Mar 20, 2024 | Andy Chen | Wolfe Research | $46.00 | $40.23 | 14.34% | -29.20% |
| Mar 19, 2024 | Justin Kim | Oppenheimer | $44.00 | $39.95 | 10.14% | -32.28% |
The latest Alpine Immune Sciences stock forecast, released on Apr 11, 2024 by Robert Driscoll from Wedbush, set a price target of $65.00, which represents a 38.18% increase from the stock price at the time of the forecast ($47.04), and a 0.05% increase from ALPN last price ($64.97).
Alpine Immune Sciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 5 |
| Avg Price Target | - | - | $55.00 |
| Last Closing Price | $64.97 | $64.97 | $64.97 |
| Upside/Downside | -100.00% | -100.00% | -15.35% |
In the current month, the average price target of Alpine Immune Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Alpine Immune Sciences's last price of $64.97. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 16, 2024 | RBC Capital | Underperform | Underperform | Hold |
| May 16, 2024 | Wedbush | Market Perform | Market Perform | Hold |
| Apr 15, 2024 | Cowen & Co. | - | Hold | Downgrade |
| Apr 12, 2024 | Leerink Partners | - | Market Perform | Downgrade |
| Apr 09, 2024 | Wedbush | Buy | Buy | Hold |
| Apr 09, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Apr 09, 2024 | Guggenheim | - | Buy | Initialise |
| Mar 19, 2024 | Wedbush | Buy | Buy | Hold |
| Jan 26, 2024 | Wedbush | Buy | Buy | Hold |
| Jan 26, 2024 | RBC Capital | Underperform | Underperform | Hold |
Alpine Immune Sciences's last stock rating was published by RBC Capital on May 16, 2024. The company gave ALPN a "Underperform" rating, the same as its previous rate.
Alpine Immune Sciences Financial Forecast
Alpine Immune Sciences Revenue Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $30.85M | - | - | $9.39M | $2.78M | - | - | $13.63M | $4.53M | $8.52M | $7.19M | $3.20M | $5.64M | $1.91M | $688.00K | $1.09M | $884.00K | $289.00K | $567.00K | - | - | $390.00K |
| Avg Forecast | $19.87M | $17.13M | $14.77M | $12.73M | $4.72M | $3.00M | $2.99M | $2.22M | $9.10M | $7.25M | $7.08M | $6.88M | $10.96M | $18.68M | $10.04M | $16.26M | $13.97M | $21.19M | $7.77M | $6.67M | $3.10M | $5.10M | $2.13M | $376.67K | $183.33K | $250.00K | $83.33K | $113.00K | $456.65K | $294.21K |
| High Forecast | $19.87M | $17.13M | $14.77M | $12.73M | $4.72M | $3.00M | $5.43M | $2.22M | $14.58M | $7.25M | $7.08M | $6.88M | $10.96M | $18.68M | $10.04M | $29.57M | $25.40M | $38.52M | $14.13M | $12.13M | $5.64M | $9.27M | $3.87M | $684.85K | $333.33K | $454.55K | $151.51K | $205.45K | $547.98K | $353.05K |
| Low Forecast | $19.87M | $17.13M | $14.77M | $12.73M | $4.72M | $3.00M | $1.63M | $2.22M | $2.61M | $7.25M | $7.08M | $6.88M | $10.96M | $18.68M | $10.04M | $8.87M | $7.62M | $11.56M | $4.24M | $3.64M | $1.69M | $2.78M | $1.16M | $205.45K | $100.00K | $136.36K | $45.45K | $61.64K | $365.32K | $235.37K |
| # Analysts | - | - | - | - | 1 | 1 | 2 | 2 | 5 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 11 | 12 | 16 | 9 | 9 | 8 | 9 | 13 | 17 | 19 | 14 |
| Surprise % | - | - | - | - | - | - | - | - | 3.39% | - | - | 1.36% | 0.25% | - | - | 0.84% | 0.32% | 0.40% | 0.93% | 0.48% | 1.82% | 0.38% | 0.32% | 2.90% | 4.82% | 1.16% | 6.80% | - | - | 1.33% |
Alpine Immune Sciences's average Quarter revenue forecast for Mar 24 based on 2 analysts is $2.22M, with a low forecast of $2.22M, and a high forecast of $2.22M. ALPN's average Quarter revenue forecast represents a -92.80% decrease compared to the company's last Quarter revenue of $30.85M (Dec 23).
Alpine Immune Sciences EBITDA Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 2 | 2 | 5 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 11 | 12 | 16 | 9 | 9 | 8 | 9 | 13 | 17 | 19 | 14 |
| EBITDA | - | - | - | - | - | - | - | - | $1.55M | - | - | $-13.20M | $-18.23M | - | - | $-7.22M | $-16.75M | $-13.06M | $-10.52M | $-10.26M | $-5.97M | $-5.78M | $-9.56M | $-5.28M | $-6.57M | $-11.05M | $-11.42M | $-12.01M | $-11.95M | $-7.99M |
| Avg Forecast | $-18.84M | $-16.24M | $-14.00M | $-12.07M | $-4.48M | $-2.85M | $-2.83M | $-4.32M | $-8.63M | $-6.88M | $-6.71M | $-4.62M | $-10.40M | $-626.24M | $-9.53M | $-4.94M | $-13.25M | $-669.77M | $-4.79M | $-7.70M | $-2.94M | $-4.53M | $-25.66M | $-7.19M | $-173.87K | $-12.02M | $-12.09M | $-12.21M | $-6.16M | $-5.39M |
| High Forecast | $-18.84M | $-16.24M | $-14.00M | $-12.07M | $-4.48M | $-2.85M | $-1.55M | $-3.46M | $-2.48M | $-6.88M | $-6.71M | $-3.70M | $-10.40M | $-500.99M | $-9.53M | $-3.95M | $-7.23M | $-535.82M | $-3.83M | $-6.16M | $-1.61M | $-3.62M | $-20.53M | $-5.75M | $-94.83K | $-9.62M | $-9.67M | $-9.77M | $-4.93M | $-4.31M |
| Low Forecast | $-18.84M | $-16.24M | $-14.00M | $-12.07M | $-4.48M | $-2.85M | $-5.15M | $-5.18M | $-13.83M | $-6.88M | $-6.71M | $-5.54M | $-10.40M | $-751.49M | $-9.53M | $-5.93M | $-24.09M | $-803.73M | $-5.75M | $-9.23M | $-5.35M | $-5.43M | $-30.80M | $-8.62M | $-316.12K | $-14.43M | $-14.51M | $-14.65M | $-7.39M | $-6.46M |
| Surprise % | - | - | - | - | - | - | - | - | -0.18% | - | - | 2.86% | 1.75% | - | - | 1.46% | 1.26% | 0.02% | 2.20% | 1.33% | 2.03% | 1.28% | 0.37% | 0.73% | 37.81% | 0.92% | 0.94% | 0.98% | 1.94% | 1.48% |
2 analysts predict ALPN's average Quarter EBITDA for Mar 24 to be $-4.32M, with a high of $-3.46M and a low of $-5.18M. This is -379.20% lower than Alpine Immune Sciences's previous annual EBITDA (Dec 23) of $1.55M.
Alpine Immune Sciences Net Income Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 2 | 2 | 5 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 11 | 12 | 16 | 9 | 9 | 8 | 9 | 13 | 17 | 19 | 14 |
| Net Income | - | - | - | - | - | - | - | - | $5.96M | - | - | $-11.01M | $-18.86M | - | - | $-7.53M | $-15.17M | $-13.49M | $-11.03M | $-10.64M | $-6.34M | $-6.14M | $-9.93M | $-5.53M | $-6.14M | $-11.47M | $-11.86M | $-12.38M | $-12.14M | $-7.91M |
| Avg Forecast | $-30.26M | $-29.60M | $-30.89M | $-30.04M | $-25.34M | $-28.08M | $-26.25M | $-4.50M | $-21.13M | $-21.41M | $-24.01M | $-4.82M | $-16.52M | $-647.25M | $-24.01M | $-5.15M | $-17.20M | $-692.24M | $-5.02M | $-7.98M | $-18.81M | $-4.80M | $-26.64M | $-7.53M | $-35.30M | $-12.49M | $-12.55M | $-12.20M | $-6.09M | $-5.33M |
| High Forecast | $-30.26M | $-29.60M | $-30.89M | $-30.04M | $-25.34M | $-28.08M | $-18.75M | $-3.60M | $-16.51M | $-21.41M | $-24.01M | $-3.85M | $-16.52M | $-517.80M | $-24.01M | $-4.12M | $-7.04M | $-553.79M | $-4.02M | $-6.39M | $-7.69M | $-3.84M | $-21.31M | $-6.03M | $-14.44M | $-9.99M | $-10.04M | $-9.76M | $-4.87M | $-4.27M |
| Low Forecast | $-30.26M | $-29.60M | $-30.89M | $-30.04M | $-25.34M | $-28.08M | $-31.25M | $-5.40M | $-25.75M | $-21.41M | $-24.01M | $-5.78M | $-16.52M | $-776.70M | $-24.01M | $-6.18M | $-35.49M | $-830.69M | $-6.02M | $-9.58M | $-38.81M | $-5.76M | $-31.97M | $-9.04M | $-72.85M | $-14.98M | $-15.06M | $-14.64M | $-7.31M | $-6.40M |
| Surprise % | - | - | - | - | - | - | - | - | -0.28% | - | - | 2.29% | 1.14% | - | - | 1.46% | 0.88% | 0.02% | 2.20% | 1.33% | 0.34% | 1.28% | 0.37% | 0.73% | 0.17% | 0.92% | 0.94% | 1.01% | 1.99% | 1.48% |
Alpine Immune Sciences's average Quarter net income forecast for Mar 24 is $-4.50M, with a range of $-5.40M to $-3.60M. ALPN's average Quarter net income forecast represents a -175.54% decrease compared to the company's last Quarter net income of $5.96M (Dec 23).
Alpine Immune Sciences SG&A Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 2 | 2 | 5 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 11 | 12 | 16 | 9 | 9 | 8 | 9 | 13 | 17 | 19 | 14 |
| SG&A | - | - | - | - | - | - | - | - | $6.37M | - | - | $5.40M | $4.39M | - | - | $4.78M | $4.54M | $3.47M | $3.29M | $3.26M | $3.05M | $2.73M | $3.34M | $1.78M | $2.10M | $2.47M | $2.55M | $2.35M | $1.86M | $1.88M |
| Avg Forecast | $32.60M | $28.10M | $24.23M | $20.89M | $7.75M | $4.93M | $4.90M | $3.64M | $14.94M | $11.90M | $11.62M | $3.05M | $17.99M | $30.66M | $16.48M | $3.27M | $22.92M | $34.77M | $1.50M | $2.44M | $5.09M | $2.13M | $3.50M | $618.07K | $300.83K | $410.23K | $136.74K | $185.42K | $749.31K | $482.77K |
| High Forecast | $32.60M | $28.10M | $24.23M | $20.89M | $7.75M | $4.93M | $8.92M | $3.64M | $23.93M | $11.90M | $11.62M | $3.67M | $17.99M | $30.66M | $16.48M | $3.92M | $41.68M | $63.21M | $1.80M | $2.93M | $9.26M | $2.56M | $6.36M | $1.12M | $546.97K | $745.86K | $248.62K | $337.13K | $899.18K | $579.32K |
| Low Forecast | $32.60M | $28.10M | $24.23M | $20.89M | $7.75M | $4.93M | $2.68M | $3.64M | $4.29M | $11.90M | $11.62M | $2.44M | $17.99M | $30.66M | $16.48M | $2.61M | $12.50M | $18.96M | $1.20M | $1.95M | $2.78M | $1.71M | $1.91M | $337.13K | $164.09K | $223.76K | $74.58K | $101.14K | $599.45K | $386.21K |
| Surprise % | - | - | - | - | - | - | - | - | 0.43% | - | - | 1.77% | 0.24% | - | - | 1.46% | 0.20% | 0.10% | 2.20% | 1.33% | 0.60% | 1.28% | 0.96% | 2.88% | 6.99% | 6.01% | 18.67% | 12.65% | 2.48% | 3.90% |
Alpine Immune Sciences's average Quarter SG&A projection for Mar 24 is $3.64M, based on 2 Wall Street analysts, with a range of $3.64M to $3.64M. The forecast indicates a -42.85% fall compared to ALPN last annual SG&A of $6.37M (Dec 23).
Alpine Immune Sciences EPS Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 2 | 2 | 5 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 11 | 12 | 16 | 9 | 9 | 8 | 9 | 13 | 17 | 19 | 14 |
| EPS | - | - | - | - | - | - | - | - | $0.15 | - | - | $-0.23 | $-0.41 | - | - | $-0.25 | $-0.52 | $-0.55 | $-0.46 | $-0.45 | $-0.27 | $-0.28 | $-0.53 | $-0.30 | $-0.33 | $-0.62 | $-0.64 | $-0.70 | $-0.88 | $-0.57 |
| Avg Forecast | $-0.47 | $-0.46 | $-0.48 | $-0.47 | $-0.40 | $-0.44 | $-0.41 | $-0.43 | $-0.33 | $-0.33 | $-0.38 | $-0.37 | $-0.26 | $-0.09 | $-0.38 | $-0.17 | $-0.28 | $0.02 | $-0.34 | $-0.36 | $-0.31 | $-0.23 | $-0.23 | $-0.47 | $-0.58 | $-0.68 | $-0.68 | $-0.69 | $-0.29 | $-0.29 |
| High Forecast | $-0.47 | $-0.46 | $-0.48 | $-0.47 | $-0.40 | $-0.44 | $-0.29 | $-0.43 | $-0.26 | $-0.33 | $-0.38 | $-0.37 | $-0.26 | $-0.09 | $-0.38 | $-0.07 | $-0.12 | $0.04 | $-0.14 | $-0.15 | $-0.13 | $-0.10 | $-0.10 | $-0.19 | $-0.24 | $-0.28 | $-0.28 | $-0.28 | $-0.23 | $-0.23 |
| Low Forecast | $-0.47 | $-0.46 | $-0.48 | $-0.47 | $-0.40 | $-0.44 | $-0.49 | $-0.43 | $-0.40 | $-0.33 | $-0.38 | $-0.37 | $-0.26 | $-0.09 | $-0.38 | $-0.35 | $-0.59 | $0.01 | $-0.71 | $-0.74 | $-0.64 | $-0.48 | $-0.48 | $-0.97 | $-1.21 | $-1.40 | $-1.40 | $-1.42 | $-0.34 | $-0.35 |
| Surprise % | - | - | - | - | - | - | - | - | -0.45% | - | - | 0.62% | 1.59% | - | - | 1.49% | 1.82% | -27.50% | 1.34% | 1.26% | 0.87% | 1.20% | 2.27% | 0.64% | 0.56% | 0.91% | 0.94% | 1.01% | 3.03% | 1.97% |
According to 2 Wall Street analysts, Alpine Immune Sciences's projected average Quarter EPS for Mar 24 is $-0.43, with a low estimate of $-0.43 and a high estimate of $-0.43. This represents a -390.00% decrease compared to ALPN previous annual EPS of $0.15 (Dec 23).
Alpine Immune Sciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCYC | Bicycle Therapeutics | $20.54 | $70.50 | 243.23% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.80 | $6.00 | 233.33% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.22 | $7.00 | 215.32% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.20 | $38.80 | 173.24% | Buy |
| IGMS | IGM Biosciences | $9.31 | $25.00 | 168.53% | Buy |
| MLYS | Mineralys Therapeutics | $11.23 | $30.00 | 167.14% | Buy |
| ACRV | Acrivon Therapeutics | $8.08 | $21.50 | 166.09% | Buy |
| STOK | Stoke Therapeutics | $14.70 | $33.33 | 126.73% | Buy |
| ADAG | Adagene | $2.61 | $5.00 | 91.57% | Buy |
| MLTX | MoonLake Immunotherapeutics | $46.02 | $79.33 | 72.38% | Buy |
| TERN | Terns Pharmaceuticals | $7.81 | $12.50 | 60.05% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.37 | $3.33 | 40.51% | Buy |
| ANAB | AnaptysBio | $35.90 | $36.33 | 1.20% | Buy |
| ALPN | Alpine Immune Sciences | $64.97 | $55.00 | -15.35% | Hold |
ALPN Forecast FAQ
Is Alpine Immune Sciences a good buy?
No, according to 5 Wall Street analysts, Alpine Immune Sciences (ALPN) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 40.00% of ALPN's total ratings.
What is ALPN's price target?
Alpine Immune Sciences (ALPN) average price target is $55 with a range of $44 to $65, implying a -15.35% from its last price of $64.97. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Alpine Immune Sciences stock go up soon?
According to Wall Street analysts' prediction for ALPN stock, the company can go down by -15.35% (from the last price of $64.97 to the average price target of $55), up by 0.05% based on the highest stock price target, and down by -32.28% based on the lowest stock price target.
Can Alpine Immune Sciences stock reach $100?
ALPN's average twelve months analyst stock price target of $55 does not support the claim that Alpine Immune Sciences can reach $100 in the near future.
What are Alpine Immune Sciences's analysts' financial forecasts?
Alpine Immune Sciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $12.93M (high $15.38M, low $11.58M), average EBITDA is $-14.48M (high $-12.328M, low $-17.664M), average net income is $-84.177M (high $-75.776M, low $-90.079M), average SG&A $21.22M (high $25.24M, low $18.99M), and average EPS is $-1.679 (high $-1.562, low $-1.757). ALPN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $64.49M (high $64.49M, low $64.49M), average EBITDA is $-61.156M (high $-61.156M, low $-61.156M), average net income is $-121M (high $-121M, low $-121M), average SG&A $105.82M (high $105.82M, low $105.82M), and average EPS is $-1.887 (high $-1.887, low $-1.887).
Did the ALPN's actual financial results beat the analysts' financial forecasts?
Based on Alpine Immune Sciences's last annual report (Dec 2023), the company's revenue was $58.88M, beating the average analysts forecast of $30.31M by 94.22%. Apple's EBITDA was $-44.25M, beating the average prediction of $-26.844M by 64.84%. The company's net income was $-32.184M, missing the average estimation of $-71.364M by -54.90%. Apple's SG&A was $22.22M, missing the average forecast of $41.51M by -46.46%. Lastly, the company's EPS was $-0.64, missing the average prediction of $-1.409 by -54.59%. In terms of the last quarterly report (Dec 2023), Alpine Immune Sciences's revenue was $30.85M, beating the average analysts' forecast of $9.1M by 238.88%. The company's EBITDA was $1.55M, missing the average prediction of $-8.634M by -117.92%. Alpine Immune Sciences's net income was $5.96M, missing the average estimation of $-21.131M by -128.21%. The company's SG&A was $6.37M, missing the average forecast of $14.94M by -57.33%. Lastly, the company's EPS was $0.15, missing the average prediction of $-0.33 by -145.45%